Study of Rhopressa® for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension in a Real-world Setting

PHASE4CompletedINTERVENTIONAL
Enrollment

261

Participants

Timeline

Start Date

December 27, 2018

Primary Completion Date

July 26, 2019

Study Completion Date

July 26, 2019

Conditions
Glaucoma, Open-AngleOcular Hypertension
Interventions
DRUG

Netarsudil Ophthalmic Solution 0.02%

1 drop in each eye once daily in the evening

Trial Locations (22)

16066

Scott & Christie and Associates, PC, Cranberry Township

19006

Valley Eye Professionals, LLC, Huntingdon Valley

21204

Glaucoma Consultants, Baltimore

29456

Carolina Cataract & Laser Center, Ladson

30076

Coastal Research Associates, LLC, Roswell

33773

Shettle Eye Research Inc, Largo

34238

Center For Sight, Sarasota

37204

Advancing Vision Research, Nashville

38119

Total Eye Care, PA, Memphis

38120

VRF Eye Specialty Group, Memphis

40241

Gaddie Eye Centers, LLC, Louisville

53405

The Eye Centers of Racine and Kenosha, Racine

60187

Wheaton Eye Clinic, Ltd, Wheaton

63128

Tekwani Vision Center, St Louis

66213

Stiles Eyecare Excellence and Glaucoma Institute, PA, Overland Park

74104

Mark J. Weiss, M.D., Inc., Tulsa

77025

Houston Eye Associates, Houston

78731

Keystone Research, Austin

79902

Cataract & Glaucoma Center, El Paso

92647

Atlantis Eyecare, Huntington Beach

92653

Harvard Eye Associates, Laguna Hills

94954

North Bay Eye Associates, Inc, Petaluma

Sponsors
All Listed Sponsors
lead

Aerie Pharmaceuticals

INDUSTRY

NCT03808688 - Study of Rhopressa® for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension in a Real-world Setting | Biotech Hunter | Biotech Hunter